Stock 2179 JIANGSU RECBIO TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Jiangsu Recbio Technology Co., Ltd. Stock

Equities

2179

CNE1000057K9

Pharmaceuticals

End-of-day quote Hong Kong S.E.
Other stock markets
 18:00:00 2024-04-25 EDT 		5-day change 1st Jan Change
9.13 CNY 0.00% Intraday chart for Jiangsu Recbio Technology Co., Ltd. -1.72% -15.93%
03-27 Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. Sign Strategic Cooperation Agreement on the New Adjuvant Vaccine Project CI
03-21 Jiangsu Recbio Technology's Loss Narrows in 2023 MT

Financials

Sales 2024 * - Sales 2025 * - Capitalization 4.05B 29.34B 5.54B
Net income 2024 * -565M -4.09B -772M Net income 2025 * -612M -4.43B -837M EV / Sales 2024 * -
Net cash position 2024 * 41.31M 299M 56.47M Net Debt 2025 * 477M 3.46B 652M EV / Sales 2025 * -
P/E ratio 2024 *
-7.1 x
P/E ratio 2025 *
-6.55 x
Employees 472
Yield 2024 *
-
Yield 2025 *
-
Free-Float 22.4%
More Fundamentals * Assessed data

Chart Jiangsu Recbio Technology Co., Ltd.

Dynamic Chart

Latest news about Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. Sign Strategic Cooperation Agreement on the New Adjuvant Vaccine Project CI
Jiangsu Recbio Technology's Loss Narrows in 2023 MT
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jiangsu Recbio Technology Co., Ltd. Announces Positive Results in the Interim Analysis of the Clinical Trial of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 in the Philippines CI
Jiangsu Recbio Logs Positive Results from Philippines Trial Of Shingles Vaccine MT
Jiangsu Recbio Technology to Extend Validity Period of Share Sale MT
Jiangsu Recbio Technology Co., Ltd.(SEHK:2179) added to S&P Global BMI Index CI
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China Approves Recbio's Clinical Trial Application for Shingles Vaccine MT
Jiangsu Recbio Technology Co., Ltd. Announces Acceptance of Clinical Trial Application for the Novel Adjuvanted Recombinant Shingles Vaccine REC610 in China and Overseas Clinical Trial Progress CI
Jiangsu Recbio Technology Selected for Morgan Stanley Capital International China Small Cap Index MT
Jiangsu Recbio Technology Co., Ltd. Announces Directorate Appointments CI
Chinese Securities Regulator Approves Jiangsu Recbio Technology's Share Issuance; Stock Sinks 3% MT
Pfizer signs strategic cooperation pact with China's Sinopharm RE
Jiangsu Recbio Technology Co., Ltd. Announces Resignation of Feng Tao as Non-Executive Director and A Member of the Nomination Committee CI
More news

Press releases Jiangsu Recbio Technology Co., Ltd.

Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines AQ
Jiangsu Recbio Technology Co., Ltd. - Inclusion of Recbio in the MSCI China Small Cap Index AQ
Jiangsu Recbio Technology Co., Ltd. - Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines AQ
Legend Capital's Portfolio Company Recbio Lists on HKEX Successfully AQ
Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology AQ
More press releases

Quotes and Performance

1 week-1.72%
Current month-6.84%
1 month-1.40%
3 months-5.39%
6 months-18.48%
Current year-15.93%
More quotes

Highs and lows

1 week
9.13
Extreme 9.13
9.30
1 month
8.00
Extreme 8
9.86
Current year
7.95
Extreme 7.95
10.86
1 year
7.95
Extreme 7.95
14.88
3 years
7.95
Extreme 7.95
28.30
5 years
7.95
Extreme 7.95
28.30
10 years
7.95
Extreme 7.95
28.30
More quotes

Managers and Directors - Jiangsu Recbio Technology Co., Ltd.

Managers TitleAgeSince
Yong Liu CEO
 Chief Executive Officer 51 12-05-17
Qing Qing Chen DFI
 Director of Finance/CFO 41 -
Jian Hui Zhang CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Ming Fai Yuen BRD
 Director/Board Member 73 21-05-08
Li Jun Xia BRD
 Director/Board Member 48 21-06-27
Hong Bin Zhou BRD
 Director/Board Member 51 20-11-01
More insiders

ETFs positioned on Jiangsu Recbio Technology Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
1.05% 4 M€ -27.92%
More ETFs positioned on Jiangsu Recbio Technology Co., Ltd.

Quotes

Date Price Change Volume
24-04-26 9.13 0.00% 38,500
24-04-25 9.13 -0.44% 39,000
24-04-24 9.17 +0.22% 31,000
24-04-23 9.15 0.00% 30,000
24-04-22 9.15 -1.51% 33,500

End-of-day quote Hong Kong S.E., April 25, 2024

More quotes

Company Profile

Jiangsu Recbio Technology Co Ltd is a China-based company mainly engaged in the research and development of vaccines. The Company has a portfolio of clinical-stage and pre-clinical stage vaccines, and its human papilloma virus (HPV) vaccine pipelines comprise of recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b. The Company also involves in the development of Covid-19 vaccines. The Company mainly distributes products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-22 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.451 CNY
Average target price
13.79 CNY
Spread / Average Target
+63.15%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
JIANGSU RECBIO TECHNOLOGY CO., LTD. Stock Jiangsu Recbio Technology Co., Ltd.
-15.93% 559M
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 2179 Stock